Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

BACKGROUND: This phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody–liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer. METHODS: Patients were enrolled in four cohorts: MM-302 monotherapy (8, 16, 30, 40, and 50 mg/m(2) ever...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Cancer
Hauptverfasser: Munster, Pamela, Krop, Ian E., LoRusso, Patricia, Ma, Cynthia, Siegel, Barry A., Shields, Anthony F., Molnár, István, Wickham, Thomas J., Reynolds, Joseph, Campbell, Karen, Hendriks, Bart S., Adiwijaya, Bambang S., Geretti, Elena, Moyo, Victor, Miller, Kathy D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6219487/
https://ncbi.nlm.nih.gov/pubmed/30361524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0235-2
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge